Stock

AZN US

ASTRAZENECA PLC · NYSE · USD · Healthcare

Insiders net buying $0.0M (90d)

$166.58

+2.02 (+1.23%)

Price session: 2026-09-25 · Observed: 25 Sept 2026, 23:00 KSA · Source: delayed quote

Easy Score

Neutral

Value

Momentum

Trend

Three engines, 0–100 each. Analysis, not financial advice.

Why is it moving?auto-generated

AZN +1.23% today · volume in line with average · 3 recent headlines — latest not assessed: “Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority R…”.

Latest headlines

• Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer• Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum• AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026

Priceinteractive — your checked tools draw on it

Daily is the finest granularity · last ~6 months

RSI (14)

Patterns detected:

CloseMA 50MA 200check tools below to add them to the chart

Key technicals & risksame engine as the score

RSI (14)

54.2

MACD hist.

+0.57

50-day MA

$164.03

200-day MA

$182.61

ATR (14)

$3.45

Avg volume (20d)

3.0M

Volatility

29%

Max drawdown

-26%

Beta vs S&P

0.30

Daily plain-language briefs are a Pro feature.

Signal mix18

bullish

neutral

bearish

Every tool the engine can compute from stored bars. Check tools on the chart to see each one.

Street consensus35 analysts

Buy28

Hold6

Sell1

Forecast two independent reads

System

USD 163.79USD 170.27

Yours · 2 tools

USD 163.79USD 170.27

Model anchor (last stored close)

USD 166.58

USD 163.40USD 170.65

Computed from: USD 166.58 · session 2026-09-25 · 2509 historical windows

Lean score +0.00 — 0 bullish / 0 bearish / 2 neutral among your checked tools, weighted for this horizon. Your overlay is an exploratory scenario, not a calibrated prediction. The historical baseline stays unchanged. The system band is the 25th–75th percentile of this stock’s own historical moves for the horizon.